Past performance does not predict future results. Informational only, not investment advice.
EWALD STEPHEN P (General Counsel & Corp. Secy. at Medpace Holdings, Inc.) reported an open-market sale of 1,245 shares of MEDP at an average $690.00, roughly $859,050, in a Form 4 filed 2026-11-02.
BURWIG SUSAN E (Exec. VP, Operations at Medpace Holdings, Inc.) reported an open-market sale of 20,000 shares of MEDP at an average $677.00, roughly $13,540,000, in a Form 4 filed 2026-10-28.
Troendle August J. (President & CEO at Medpace Holdings, Inc.) reported an open-market sale of 48,667 shares of MEDP at an average $623.03, roughly $30,320,929, in a Form 4 filed 2026-10-01.
Carley Brian T (Director at Medpace Holdings, Inc.) reported an open-market sale of 5,000 shares of MEDP at an average $608.63, roughly $3,043,150, in a Form 4 filed 2026-08-21.
DAVENPORT FRED B JR (Director at Medpace Holdings, Inc.) reported an open-market sale of 7,283 shares of MEDP at an average $606.15, roughly $4,414,590, in a Form 4 filed 2026-08-21.
Troendle August J. (President & CEO at Medpace Holdings, Inc.) reported an open-market sale of 11,824 shares of MEDP at an average $601.49, roughly $7,111,969, in a Form 4 filed 2026-08-14.
McCarthy Cornelius P. III (Director at Medpace Holdings, Inc.) reported an open-market sale of 1,140 shares of MEDP at an average $605.37, roughly $690,122, in a Form 4 filed 2026-08-13.
Troendle August J. (President & CEO at Medpace Holdings, Inc.) reported an open-market sale of 23,144 shares of MEDP at an average $604.25, roughly $13,984,854, in a Form 4 filed 2026-08-12.
McCarthy Cornelius P. III (Director at Medpace Holdings, Inc.) reported an open-market sale of 795 shares of MEDP at an average $585.07, roughly $465,131, in a Form 4 filed 2026-08-11.
End of results.